242 related articles for article (PubMed ID: 17041104)
1. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST
Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104
[TBL] [Abstract][Full Text] [Related]
2. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.
Murakami T; Maki W; Cardones AR; Fang H; Tun Kyi A; Nestle FO; Hwang ST
Cancer Res; 2002 Dec; 62(24):7328-34. PubMed ID: 12499276
[TBL] [Abstract][Full Text] [Related]
3. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
4. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin.
Cardones AR; Murakami T; Hwang ST
Cancer Res; 2003 Oct; 63(20):6751-7. PubMed ID: 14583470
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
6. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.
Portella L; Vitale R; De Luca S; D'Alterio C; Ieranò C; Napolitano M; Riccio A; Polimeno MN; Monfregola L; Barbieri A; Luciano A; Ciarmiello A; Arra C; Castello G; Amodeo P; Scala S
PLoS One; 2013; 8(9):e74548. PubMed ID: 24058588
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
9. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
[TBL] [Abstract][Full Text] [Related]
10. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
11. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
12. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of stromal CXCR4 impairs development of lung metastases.
D'Alterio C; Barbieri A; Portella L; Palma G; Polimeno M; Riccio A; Ieranò C; Franco R; Scognamiglio G; Bryce J; Luciano A; Rea D; Arra C; Scala S
Cancer Immunol Immunother; 2012 Oct; 61(10):1713-20. PubMed ID: 22399057
[TBL] [Abstract][Full Text] [Related]
14. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
Murakami T; Zhang TY; Koyanagi Y; Tanaka Y; Kim J; Suzuki Y; Minoguchi S; Tamamura H; Waki M; Matsumoto A; Fujii N; Shida H; Hoxie JA; Peiper SC; Yamamoto N
J Virol; 1999 Sep; 73(9):7489-96. PubMed ID: 10438838
[TBL] [Abstract][Full Text] [Related]
17. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
18. CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.
Ieranò C; D'Alterio C; Giarra S; Napolitano M; Rea G; Portella L; Santagata A; Trotta AM; Barbieri A; Campani V; Luciano A; Arra C; Anniciello AM; Botti G; Mayol L; De Rosa G; Pacelli R; Scala S
Cell Death Dis; 2019 Jul; 10(8):562. PubMed ID: 31332163
[TBL] [Abstract][Full Text] [Related]
19. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis.
Ieranò C; Portella L; Lusa S; Salzano G; D'Alterio C; Napolitano M; Buoncervello M; Macchia D; Spada M; Barbieri A; Luciano A; Barone MV; Gabriele L; Caraglia M; Arra C; De Rosa G; Scala S
Nanoscale; 2016 Apr; 8(14):7562-71. PubMed ID: 26983756
[TBL] [Abstract][Full Text] [Related]
20. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.
Bertolini G; Cancila V; Milione M; Lo Russo G; Fortunato O; Zaffaroni N; Tortoreto M; Centonze G; Chiodoni C; Facchinetti F; Pollaci G; Taiè G; Giovinazzo F; Moro M; Camisaschi C; De Toma A; D'Alterio C; Pastorino U; Tripodo C; Scala S; Sozzi G; Roz L
Mol Ther; 2021 Oct; 29(10):2963-2978. PubMed ID: 34023505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
